[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Chlamydia Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 50 pages | ID: C09EC5F4925FEN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Chlamydia Infections Drug pipeline report- 2020 is an annual R&D review of Chlamydia Infections pipeline candidates. The report presents the current status of all major Chlamydia Infections therapeutic compounds. Detailed insights into Chlamydia Infections pipeline development, current status, companies, drug profiles and Chlamydia Infections preclinical and clinical trials are included.

2020 Chlamydia Infections Pipeline Market Insights
Chlamydia Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Chlamydia Infections therapies, pipeline by phase and others are included.

Chlamydia Infections pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Chlamydia Infections Therapeutic Drug candidates
Both active and inactive Chlamydia Infections pipeline drug candidates are included in the report

Chlamydia Infections Clinical Trials and preclinical Studies
Chlamydia Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Chlamydia Infections pipeline market developments
Chlamydia Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Chlamydia Infections pipeline companies in active development
The report analyzes Chlamydia Infections pipeline of the below companies-

Abera Bioscience AB, Abivax SA, BlueWillow Biologics, Evofem Biosciences Inc, Genetic Immunity Inc, Lead Discovery Center GmbH, Merck & Co Inc, Prokarium Ltd, QureTech Bio AB, SATT IDF Innov, Vault Pharma Inc, Melinta Therapeutics Inc

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
12 Companies investing in Chlamydia Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Chlamydia Infections pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. CHLAMYDIA INFECTIONS PIPELINE MARKET INSIGHTS, 2020

1.1 Chlamydia Infections Disease Overview
1.2 Chlamydia Infections Drug Pipeline Snapshot, 2020
  1.2.1 Chlamydia Infections Pipeline Drugs by Phase
  1.2.2 Chlamydia Infections Pipeline Drugs by Company
  1.2.3 Chlamydia Infections Pipeline Drugs by Mechanism of Action
  1.2.4 Chlamydia Infections Pipeline Drugs by Route of Administration

2. CHLAMYDIA INFECTIONS COMPANY WISE PIPELINE DETAILS

Abera Bioscience AB Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Abivax SA Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
BlueWillow Biologics Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Evofem Biosciences Inc Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Genetic Immunity Inc Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Lead Discovery Center GmbH Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Merck & Co Inc Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Prokarium Ltd Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
QureTech Bio AB Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
SATT IDF Innov Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Vault Pharma Inc Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Melinta Therapeutics Inc Chlamydia Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. CHLAMYDIA INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. CHLAMYDIA INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications